Semaglutide shortage ends as FDA sets deadline for compounders
With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed – for now.
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List
On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide drug shortage has been resolved. The timing of this order was unexpected due to the ongoing litigation between FDA and the Outsourcing Facilities Association (OFA) involving tirzepatide,
Drug compounders sue over weight loss drugs’ removal from FDA shortage list
A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for removing semaglutide, the active ingredient in Ozempic, from its drug shortage list.
Compounders sue FDA again over declaring end of shortage for Novo's semaglutide
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight. | Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight.
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group has sued the U.
FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market, for now
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply.  | The demand for weight loss drugs is not slowing down,
Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's weight-loss and diabetes treatments Wegovy and Ozempic from its shortage list,
FDA removes semaglutide from drug shortage list
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk and the FDA announced. On Feb. 21,
Drug compounders sue FDA over declaration ending Wegovy shortage
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” but in earnings Monday still forecast higher revenue and profits in 2025.
Off-brand weight-loss drug makers are suing the FDA, again
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another lawsuit against the U.S. Food and Drug Administration (FDA). This time, it’s over the health regulator’s decision to remove semaglutide — the active ingredient in Novo Nordisk’s (NVO) popular Ozempic and Wegovy treatments — from its drug shortage list.
Healio8h
Top in endocrinology: Semaglutide shortage ends; rise in diabetes in low-income countries
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...